StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Total non-GAAP adjustments after tax by Year

Total non-GAAP adjustments after tax ($M) ($M)

Gilead Sciences Total non-GAAP adjustments after tax: $1,719M in FY2025, down 67.7% from a year earlier. That is the lowest of the 10 years on record here.

Latest, FY2025
1,719
Period ended Dec 31, 2025
Change on a year earlier
-67.7%
5,315 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| Total non-GAAP adjustments to net income attributable to Gilead | $ | 146 | $ | 607 | $ | 1,719 | $ | 5,315”

Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗

Reported in Form 8-K GAAP to Non-GAAP Reconciliation.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Gilead Sciences Total non-GAAP adjustments after tax ($M), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng-adj-after-tax

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.